Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the cast study

Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction.N Engl J Med 1977;64:297–305. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.Circulation 1984;69:250–257. Mukharji J, Rude RE, Poole WK et al. and the MILIS study group. Risk factors for sudden death after acute myocardial infarction: Two year follow-up.Am J Cardiol 1984;54:31–35. Ahnve S, Gilpin E, Henninng H, et al. Limitations and advantages of the ejection fraction for defining high risk after acute myocardial infarction.Am J Cardiol 1986;59:872–878. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction.Am J Cardiol 1987;59:256–262. Kostis JB, Byington R, Friedman LM, et al. for the BHAT Study Group. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction.J Am Coll Cardiol 1987;10:231–242. Scheidt S. Ventricular premature complexes as villains: Still an important part of the problem.J Am Coll Cardiol 1987;10:243–245. Bayés de Luna A, Brugada P, Cosin J, Navarro F.Sudden cardiac death. Dordrecht: Kluwer Academic, 1990, in press. Collaborative Group. Phenytoin after recovery from myocardial infarction: Controlled trial in 568 patients.Lancet 1971;2:1055–1057. Peter T, Ross D, Duffield A et al. Effect on survival after myocardial infarction of long-term treatment with phenytoin.Br Heart J 1978;40:1356–1360. Ryden L, Arnman K, Conradson T-B, et al. Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction.Am Heart J 1980;100:1006–1012. Bastian BC, McFarlane PW, McLauchlan JH, et al. A prospective randomized trial of tocainide in patients following myocardial infarction.Am Heart J 1980;100:1017–1022. Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexiletine in high-risk patients after myocardial infarction.Lancet 1980;2:1324–1327. IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings.J Am Coll Cardiol 1984;4:1148–1163. Van Durme JP, Hagemeijer F, Bogaert M, et al. Chronic antidysrhythmic treatment after myocardial infarction. Design of the Gent-Roterdam Aprindine study. In: Boissel JP, Klimt CR, eds.Multicenter controlled trials: Principles and problems. Paris: INSERM, 1977:43–48. Julian DE. Arrhythmogenic effects of antiarrhythmic drugs.Eur Heart J 1988;9(Suppl B):1–4. Hoffman A, Schütz E, White R, et al. Suppression of highgrade ventricular ectopic activity by antiarrhythmic drug treatment as a marker for survival in patients with chronic coronary artery disease.Am Heart J 1984;107:1103–1108. Grupo de Investigadores del EEMS. Ensayo multicéntrico sobre la prevención de la muerte súbita con agentes antiarritmicos en el postinfarto de miocardio.Rev. Esp Cardiol 1989;42:77–83. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Recruitment and baseline description of patients in the cardiac Arrhythmia Pilot Study.Am J Cardiol 1988;61:704–713. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effect of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: The CAPS.Am J Cardiol 1988;61:501–509. CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989;321:406–412. Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST).N Engl J Med 1989;321:386–383. Parré J, Brugada P. Extrasistoles ventriculares postinfarto y el uso de fármacos antiarritmicos: un peligro anticipado por los electrofisiólogos.Rev Esp Cardiol 1989;42:498–501. Podrid PJ, Marcus FI. Lessons to be learned from the Cardiac Arrhythmia Suppression Trial.Am J Cardiol 1989;64: 1189–1191. Garratt C, Ward DE, Camm AJ. Lessons from the Cardiac Arrhythmias Suppression Trial.Br Med J 1989;299:805–806. Baker BJ, Dinh MA, Kroskey D, et al. Effect of propafenone on left ventricular ejection fraction.Am J Cardiol 1984;54:20D-22D. Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs.J Am Coll Cardiol 1989;14:1326–1330. Bayés de Luna A, Guindo J, Torner P, et al. Value of effort testing and acute drug testing in the evaluation of antiarrhythmic treatment.Eur Heart J 1987;8(Suppl A):77–82. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.N Engl J Med 1981;304:801–807. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.JAMA 1982;247: 1707–1714. Members of Trial Research Committee. Improvement in prognosis of myocardial infarction by long-term β-adrenoreceptor blockade using practolol. A multicenter international study.Br Med J 1975:3:735–740. Taylor SH, Silke B, Ebbut A, et al. Long-term prevention study with oxprenolol in coronary heart disease.N Engl J Med 1982;307:1293–1301. Wilhelmsson C, Vedin JA, Wilhelmsen L, et al. Reduction of sudden deaths alter myocardial infarction by treatment with alprenolol. Preliminary results.Lancet 1974;2:1157–1160. Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction.Eur Heart J 1983;4:367–375. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction.Lancet 1982;1:1142–1147. Hjamarson A, Elmfeldt D, Herlitz J et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial.Lancet 1981;2:823–827. Bayés de Luna A, Coumel PH, Leclercq JF. Ambulatory sudden death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.Am Heart J 1989;117:151–157. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.Br Heart J 1985;53:412–421. Domínguez de Rozas JM, Garcia J, Guindo J, et al. Amiodarone as a drug of first choice in the prevention of sustained ventricular tachycardia and/or fibrillation. In: Bayés de Luna A, Betriu A, Permanyer G, eds.Cardiovascular therapy. Dordrecht: Martinus Nijhoff, 1988:92–97. Nademaee K, Hendrickson JA, Cisnom DS, et al. Control of refractory life-threatening ventricular tachyarrhythmia by amiodarone.Am Heart J 1981;101:759–766. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congrestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).N Engl J Med 1987;316:1429–1435. Cohn JN, Archibald DG, Zeiesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.N Engl J Med 1986;314:1547–1552. Roden DM, Woosley RL. Drug therapy. Flecainide.N Engl J Med 1986;315:36–41. Berns E, Rinkenberg RL, Jeang MK, et al. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.Am J Cardiol 1987;59:1337–1341. Chimienti M, Li Bergolis M, Moizi M, Salerno JA. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.J Am Coll Cardiol 1989;14:992–998. Kunze KP, Hoffman M, Kuck KH. A prospective study of intravenous and oral flecainide in right ventricle arrhythmia.J Am Coll Cardiol 1988;11:56. Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs.Circulation 1982;65:886–894.